<DOC>
	<DOCNO>NCT01732692</DOCNO>
	<brief_summary>To compare colon cleanse quality induce 2 different mode MOVIPREP® intake 5 colon segment prior colonoscopy .</brief_summary>
	<brief_title>Evaluation Efficacy , Safety Tolerance Experimental Morning-only MOVIPREP® Bowel Preparation Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation</brief_title>
	<detailed_description>All participant enrol study allocate one two arm . Patients experimental morning-only regimen arm prepare take MOVIPREP® solution full dose - 2 litre MOVIPREP® preparation early morning day colonoscopy clinical procedure . Participants standard split-dose regimen arm prepare take MOVIPREP® solution split dose - ½ dose ( 1 litre ) even + ½ dose ( 1 litre ) MOVIPREP® preparation morning day colonoscopy . The study consist three visit . Participation study last 11 day ; 3 day minimum . There follow-up period plan except case adverse event ( AEs ) follow-up period last participant recover AE-related query participant resolve .</detailed_description>
	<criteria>male female ≥18 year ≤ 85 year colonoscopy procedure indicate willing stay outpatient clinical site colonoscopy questionnaire completion willing able undergo studyrelated procedure inform consent sign patient participation study negative pregnancy test woman childbearing potential consent double barrier method birth control subject , men woman , study ileus suspect colonic tumor manifestation intestinal obstruction delay gastric emptying ( gastroparesis ) , weak vomit reflex , tendency aspiration regurgitation toxic megacolon result severe inflammatory condition colon include Crohn 's disease ulcerative colitis suspect intestinal perforation risk gastrointestinal perforation sign severe intestinal bleeding acute inflammatory anal perianal pathology severe concomitant diseases internal organ psychiatric disease aggravation stage hypersensitivity polyethylene glycol and/or component MOVIPREP® preparation phenylketonuria diagnose glucose6phosphate dehydrogenate deficiency unconsciousness dehydration severe inflammatory disease acute abdominal pain unknown etiology pregnancy lactation period participation clinical study ( include study experimental device ) 30 day prior participation present trial patient test positive human immunodeficiency virus ( HIV ) /autoimmune disease ( AID ) , Wasserman reaction ( RW ) hepatitis B virus ( HBC ) condition circumstance , opinion Investigator , would compromise safety participant quality study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Bowel preparation , MOVIPREP®</keyword>
</DOC>